A single injection of the peptide anxiolytic selank eliminated withdrawal anxiety and prevented pain hypersensitivity in alcohol-dependent rats without affecting their drinking behavior.
One injection, two symptoms eliminatedA single 0.3 mg/kg dose of selank abolished both withdrawal anxiety and mechanical pain hypersensitivity in alcohol-dependent rats
What the researchers found
A single intraperitoneal injection of selank at 0.3 mg/kg eliminated anxiety caused by alcohol withdrawal in rats, as measured by the elevated plus maze and social interaction tests. Selank also prevented the development of mechanical allodynia (pain hypersensitivity) — a common withdrawal symptom. Notably, selank reduced withdrawal symptoms without affecting the rats' ethanol consumption, meaning it treated the withdrawal without changing drinking behavior.
Why it matters
Alcohol withdrawal is a dangerous medical condition that can include severe anxiety, pain sensitization, seizures, and even death. Current treatments (primarily benzodiazepines) carry their own addiction risk. Selank — a synthetic peptide anxiolytic derived from the natural immunopeptide tuftsin — showed the ability to address both the anxiety and pain components of withdrawal without sedation or affecting alcohol intake, suggesting it could be a safer alternative.
The numbers in context
0.3 mg/kg selank (single IP injection) · 48-hour acute withdrawal model · 24 weeks of 10% ethanol exposure · Alcohol-preferring rats (>5.0 g/kg daily intake) · Eliminated anxiety + prevented allodynia
How the study worked
Outbred rats were given 10% ethanol as their only fluid source for 24 weeks to establish stable alcohol dependence. Alcohol-preferring animals (consuming >5.0 g/kg/day) were selected. After 48 hours of acute withdrawal, rats received a single intraperitoneal injection of selank (0.3 mg/kg). Anxiety was measured using the elevated plus maze and social interaction tests. Pain sensitivity (mechanical allodynia) was also assessed. A free-choice ethanol/water test measured whether selank affected drinking behavior.
What this study cannot tell us
This is a rat study with a single dose and single time point — it doesn't address whether selank works with repeated dosing or during prolonged withdrawal. Intraperitoneal injection doesn't reflect typical human administration routes. The study used outbred rats selected for alcohol preference, which may not model all human alcohol dependence patterns. Sample sizes are not specified in the abstract.
How to read the evidence
This is a preclinical rat study with well-established behavioral assays (elevated plus maze, social interaction test). The study design is solid but limited by being a single-dose, single-timepoint experiment in animals with no human translation data.
When this study was published
Published in 2014, this study is part of the ongoing Russian selank research program. Selank remains approved in Russia but has not entered Western clinical trials for alcohol withdrawal.
The bigger picture
Selank is a Russian-developed heptapeptide that has been approved in Russia as an anxiolytic. It's derived from tuftsin, a naturally occurring immunomodulatory peptide. This study adds to a body of Russian-language research suggesting selank has legitimate anti-anxiety properties without the sedation, tolerance, or addiction risk associated with benzodiazepines. The dual action against both anxiety and pain during withdrawal is particularly interesting, as these symptoms often drive relapse. However, selank remains largely outside Western regulatory frameworks.
Questions still open
- Would selank be effective in humans experiencing alcohol withdrawal, and could it reduce benzodiazepine use in withdrawal protocols?
- Does selank's effect on withdrawal anxiety persist with repeated dosing, or does tolerance develop?
- Could selank's anti-allodynia effect during withdrawal extend to other chronic pain conditions?
Common questions
What is selank and how is it different from benzodiazepines?
Why didn't selank reduce the rats' alcohol drinking?
Read the original research
Efficacy of peptide anxiolytic selank during modeling of withdrawal syndrome in rats with stable alcoholic motivation.
Bulletin of experimental biology and medicine, 157(1), 52-5
Citation
Kolik, L G; Nadorova, A V; Kozlovskaya, M M. (2014). Efficacy of peptide anxiolytic selank during modeling of withdrawal syndrome in rats with stable alcoholic motivation.. Bulletin of experimental biology and medicine, 157(1), 52-5. https://doi.org/10.1007/s10517-014-2490-4